Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Pioglitazone use was linked to hair regrowth in a patient with permanent hair loss from cicatricial alopecia.

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Two patients with psoriasis grew extra hair after using certain psoriasis medications.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Intralesional cidofovir might be a viable alternative treatment for certain conditions.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

ICL is a condition with low CD4+ T cells like AIDS but not caused by HIV, and normal CD4+ T cell counts may vary between men and women.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

PROTACs show promise for cancer treatment, but designing them effectively is challenging.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

Certain medications can cause serious side effects, so it's important to report them.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Oclacitinib effectively treated a diabetic cat's severe skin issues without raising glucose levels, and surgery fixed eyelid fusion.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

The study found a specific peptide that helps detect TGase 3 activity in skin and hair follicles.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

IL-17 inhibitors for psoriasis may cause unexpected hair loss.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

The combination therapy was effective and well-tolerated, especially in young patients.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Blocking CISD1 reduces hearing loss from cisplatin in mice.

The research found that a protein called caveolin-1 is reduced in psoriasis, but reintroducing it can help alleviate some psoriasis symptoms.

Infections during JAK inhibitor treatment for alopecia areata are usually manageable and rarely stop treatment permanently.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.